Fig. 2: Efficacy and toxicity of apatinib in sarcoma patients.
From: Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety
a Overall responses of 59 patients with stage IV sarcoma treated with apatinib. Among 59 patients, 51 had measurable lesions and eight patients had unmeasurable lesions. Responses were PR in nine (15.25%), SD in 25 (42.37%), and PD in 25 (42.37%). b, c PFS and OS in 59 patients treated with apatinib. b Median PFS was 7.93 months; PFR at 12 weeks was 74%. c Median OS was 17.27 months. d, e Frequency and prognostic role of apatinib toxicity in sarcoma patients. d Severe adverse events (AEs) included no grade 4 AEs and grade 3 AEs in nine patients (14.06%), mainly hypertension (HTN), hand-foot syndrome (HFS), proteinuria, fatigue, and dysgeusia. e: HTN, proteinuria, and HFS were significantly correlated with longer OS in this cohort, and patients who suffered from any of these three AEs during treatment had significantly longer OS than those without these AEs
